Association of ABCC2  polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin

Pharmacogenomics
Na LiuMan Zhang

Abstract

The clinical benefits of lipid-lowering therapy with statins are widely recognized. However, the lipid-lowering efficacy of statins shows significant differences between individuals. ABCC2 has been demonstrated to contribute to the transmembrane transport of the substrate compounds. The ABCC2 SNPs may be important factors that affect individual differences in clinical drug response. The aim of this study was to evaluate the association of rs717620 of ABCC2 with treatment response to simvastatin in a Chinese Han population. A total of 318 subjects were medicated with simvastatin 20 mg/day for 12 weeks after enrollment. Venous blood was obtained before and after simvastatin treatment for measurement of blood lipid profile. Subjects were classified into high-response and low-response groups depending on whether their lipid profile change was higher or lower than median change values. The ABCC2 SNP rs717620 was genotyped from blood samples with a snapshot assay. A total of 12 weeks of treatment with simvastatin significantly decreased low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs) and significantly increased high-density lipoprotein cholesterol (HDL-C; p < 0.05). In multivariate analysis, t...Continue Reading

References

Sep 25, 1995·Archives of Internal Medicine·T A JacobsonJ C LaRosa
Nov 19, 2004·Drug Metabolism and Pharmacokinetics·Rieko Tachibana-IimoriTetsuro Miki
Apr 2, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jonathan M MaherCurtis D Klaassen
Sep 24, 2005·European Journal of Clinical Investigation·D RostA Stiehl
Nov 17, 2006·Pharmacogenetics and Genomics·Marja K PasanenMikko Niemi
Apr 9, 2013·Toxicology and Applied Pharmacology·Lucy C J EllisRichard J Weaver
Aug 26, 2014·Acta Pharmacologica Sinica·Dan XuXiao-dong Liu
Nov 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Lori W E van der SchoorJohan W Jonker
Mar 15, 2015·Drug Design, Development and Therapy·Jin Ah JungWooseong Huh
Apr 26, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maite R AranaSilvina S M Villanueva
Oct 14, 2016·Journal of Atherosclerosis and Thrombosis·Ryo NaitoHiroyuki Daida
Nov 7, 2016·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Long QianZhi-Cheng Gong
Nov 14, 2016·JAMA : the Journal of the American Medical Association·Roger ChouThomas L Jeanne
Jan 10, 2017·International Journal of Molecular Sciences·Elena ArrigoniAntonello Di Paolo
Feb 25, 2017·Clinical Research in Cardiology Supplements·P GrützmacherC Kleinert

❮ Previous
Next ❯

Citations

Jan 18, 2019·Circulation Research·Natalie C WardRobert H Eckel
Aug 23, 2019·Journal of Clinical Pharmacy and Therapeutics·Zi-Wan GuanYan Li
May 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zhiqiang HeNianlong Yan
Jan 19, 2021·Expert Opinion on Drug Metabolism & Toxicology·Henrike Bruckmueller, Ingolf Cascorbi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS
GeneScan

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.